162 related articles for article (PubMed ID: 35383292)
21. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72.
Reinbold M; Luo JL; Nedelko T; Jerchow B; Murphy ME; Whibley C; Wei Q; Hollstein M
Oncogene; 2008 Apr; 27(19):2788-94. PubMed ID: 17998932
[TBL] [Abstract][Full Text] [Related]
22. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women.
Bhattacharya P; Sengupta S
Gynecol Oncol; 2005 Oct; 99(1):176-82. PubMed ID: 16054204
[TBL] [Abstract][Full Text] [Related]
23. The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype.
Hebert-Magee S; Yu H; Behring M; Jadhav T; Shanmugam C; Frost A; Eltoum IE; Varambally S; Manne U
PLoS One; 2019; 14(2):e0211734. PubMed ID: 30730944
[TBL] [Abstract][Full Text] [Related]
24. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
[TBL] [Abstract][Full Text] [Related]
25. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer.
Schneider-Stock R; Boltze C; Peters B; Szibor R; Landt O; Meyer F; Roessner A
Neoplasia; 2004; 6(5):529-35. PubMed ID: 15548361
[TBL] [Abstract][Full Text] [Related]
26. p53 Is Potentially Regulated by Cyclophilin D in the Triple-Proline Loop of the DNA Binding Domain.
Kumutima J; Yao XQ; Hamelberg D
Biochemistry; 2021 Mar; 60(8):597-606. PubMed ID: 33591178
[TBL] [Abstract][Full Text] [Related]
27. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
28. The prolyl cis/trans isomerase cyclophilin 18 interacts with the tumor suppressor p53 and modifies its functions in cell cycle regulation and apoptosis.
Baum N; Schiene-Fischer C; Frost M; Schumann M; Sabapathy K; Ohlenschläger O; Grosse F; Schlott B
Oncogene; 2009 Nov; 28(44):3915-25. PubMed ID: 19718045
[TBL] [Abstract][Full Text] [Related]
29. The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning.
Golubovskaya VM; Finch R; Zheng M; Kurenova EV; Cance WG
Biochem J; 2008 Apr; 411(1):151-60. PubMed ID: 18215142
[TBL] [Abstract][Full Text] [Related]
30. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India.
Saranath D; Khan Z; Tandle AT; Dedhia P; Sharma B; Contractor R; Shrivastava S; Dinshaw K
Gynecol Oncol; 2002 Aug; 86(2):157-62. PubMed ID: 12144822
[TBL] [Abstract][Full Text] [Related]
31. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis.
Buller RE; Sood A; Fullenkamp C; Sorosky J; Powills K; Anderson B
Cancer Gene Ther; 1997; 4(4):239-45. PubMed ID: 9253509
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
33. Disrupting TP53 in mouse models of human cancers.
Parant JM; Lozano G
Hum Mutat; 2003 Mar; 21(3):321-6. PubMed ID: 12619119
[TBL] [Abstract][Full Text] [Related]
34. Mutational analysis of the p53 core domain L1 loop.
Zupnick A; Prives C
J Biol Chem; 2006 Jul; 281(29):20464-73. PubMed ID: 16687402
[TBL] [Abstract][Full Text] [Related]
35. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutation, allelism and survival in non-small cell lung cancer.
Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
[TBL] [Abstract][Full Text] [Related]
37. Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain.
Rollenhagen C; Chène P
Int J Cancer; 1998 Oct; 78(3):372-6. PubMed ID: 9766574
[TBL] [Abstract][Full Text] [Related]
38. The proline form of p53 codon 72 polymorphism is associated with endometriosis.
Chang CC; Hsieh YY; Tsai FJ; Tsai CH; Tsai HD; Lin CC
Fertil Steril; 2002 Jan; 77(1):43-5. PubMed ID: 11779589
[TBL] [Abstract][Full Text] [Related]
39. Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer.
Lai KC; Chen WC; Tsai FJ; Li SY; Jeng LB
Hepatogastroenterology; 2005; 52(63):944-8. PubMed ID: 15966238
[TBL] [Abstract][Full Text] [Related]
40. Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk.
Nan H; Qureshi AA; Hunter DJ; Han J
Br J Dermatol; 2008 Aug; 159(2):314-21. PubMed ID: 18510673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
